Galangin Therapeutic Applications in Cancer and Metabolic Disorders

Galangin is a naturally occurring flavonoid predominantly found in the rhizome of Alpinia officinarum and in certain types of honey. Over the past decade, it has attracted considerable attention for its dual capacity to modulate tumour cell behaviour and to improve metabolic parameters in models of diabetes and dyslipidaemia. In oncological contexts, galangin exerts cytostatic and pro-apoptotic effects through interference with key intracellular signalling pathways and transcriptional programmes. In parallel, its antioxidant and anti-inflammatory actions underlie improvements in hyperglycaemia, lipid profiles and mitochondrial function in preclinical models of metabolic disease. Collectively, these attributes position galangin as a promising scaffold for the development of novel therapeutics targeting both malignant and metabolic disorders. Emerging evidence emphasises its potential for combination regimens, in which it may enhance sensitivity to established anticancer agents and mitigate the systemic complications of diabetes.

Research from Nature Portfolio

Recent studies have demonstrated that galangin can overcome resistance to death-receptor-mediated apoptosis in renal carcinoma cells. When combined with TRAIL, a ligand that induces programmed cell death, galangin promoted the proteasomal degradation of anti-apoptotic proteins—including Bcl-2, cFLIP, Mcl-1 and survivin—thereby restoring apoptotic sensitivity in otherwise refractory cancer cells. This effect was achieved without compromising the viability of normal renal cells, suggesting a degree of tumour selectivity. Mechanistic analysis revealed that galangin inhibits NF-κB activation, leading to transcriptional down-regulation of survival factors, while simultaneously increasing proteasome activity to accelerate post-translational turnover of anti-apoptotic regulators. These findings underscore galangin’s utility as a sensitiser in TRAIL-based cancer therapies.

Galangin Therapeutic Applications in Cancer and Metabolic Disorders publication trend

The graph below shows the total number of articles in galangin therapeutic applications in cancer and metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Flavonoid: A class of plant-derived polyphenolic compounds with diverse biological activities, including antioxidant and anti-inflammatory effects.

Apoptosis: Programmed cell death characterised by chromatin condensation, membrane blebbing and caspase activation, essential for tissue homeostasis and cancer suppression.

Reactive oxygen species (ROS): Chemically reactive molecules containing oxygen (e.g. superoxide, hydrogen peroxide) that modulate signalling but can cause cellular damage at high levels.

Signal transducer and activator of transcription 3 (STAT3): A transcription factor activated by phosphorylation that promotes cell proliferation and survival in various cancers.

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL): A cytokine that triggers apoptosis selectively in tumour cells by binding to death receptors.

Nuclear factor kappa B (NF-κB): A transcription factor complex that regulates genes involved in inflammation, immunity and cell survival; often constitutively active in cancer.

Hyperglycaemia: An elevated level of glucose in the blood, characteristic of diabetes mellitus and associated with vascular and organ damage.

References

1. Flavonoids: A treasure house of prospective pharmacological potentials. Heliyon (2024).
2. Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells. Scientific Reports (2016).
3. Galangin Inhibits Gastric Cancer Growth Through Enhancing STAT3 Mediated ROS Production. Frontiers in Pharmacology (2021).
4. Galangin, a dietary flavonoid, ameliorates hyperglycaemia and lipid abnormalities in rats with streptozotocin-induced hyperglycaemia. Pharmaceutical Biology (2018).
5. Galangin, a natural flavonoid reduces mitochondrial oxidative damage in streptozotocin-induced diabetic rats. Redox Report (2017).